Clinical trials: Androgens
Prostate Cancer
Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer
The purpose of this study is to determine if the combination therapy of Hormone, Paclitaxel and Radiation therapy are effective in treatment of locally advanced prostate cancer
- Trial name
- NCT02911350
- Testing
- Hormone Suppressors, Paclitaxel, Radiation Therapy
- Volunteers
- 23 people
- Sponsor
- NYU Langone Health
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00536991
- Testing
- Calcitriol, Ketoconazole, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer, Prostatic Neoplasms
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
This study evaluates if itraconazole causes a reduction in the serum levels of prostate-specific antigen (PSA) in male subjects with castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Prostatic Neoplasms, Castrate-resistant Prostate Cancer (CRPC), Androgen-insensitive Prostate Cancer
- Trial name
- NCT01450683
- Testing
- Itraconazole
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Poor Ovarian Response
Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study
Until now no scientific clinical evidence exists regarding the possible impact of long term endogenous androgen priming in IVF patients aligned with the Bologna Criteria, in specific the impact of priming on serum parameters…
- Trial name
- NCT03447184
- Testing
- Androgen priming
- Where
- Vietnam
- Volunteers
- 30 people
- Sponsor
- Mỹ Đức Hospital
Prostate Cancer
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer…
- Trial name
- ARN-509 (NCT03488810)
- Testing
- Radiation Therapy, Apalutamide, Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High-Risk Prostate Cancer
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk…
- Trial name
- SNARE (NCT05593497)
- Testing
- Capivasertib, abiraterone acetate
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
The purpose of this research study is to determine if an investigational drug called Exisulind will extend the "off-treatment" period of patients receiving Intermittent Androgen Suppression (ADT).
- Trial name
- NCT00283803
- Testing
- Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
- Trial name
- NCT05053152
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 245 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- NRG Oncology
Metastatic Castration Resistant Prostate Cancer
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or…
- Trial name
- Himalayas-1 (NCT07723248)
- Testing
- Rinzimetostat, Darolutamide, Enzalutamide
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 600 people
- Sponsor
- ORIC Pharmaceuticals
Prostate Cancer
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
This is an open label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with metastatic CRPC at Screening. Dose escalation uses a 3+3 design to determine the maximum tolerated dose (MTD).
- Trial name
- NCT04677855
- Testing
- PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone
- Where
- 4 sites in United States, Australia
- Volunteers
- 7 people
- Sponsor
- Pellficure Pharmaceuticals, Inc
Prostate Cancer
Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer
This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy.
- Trial name
- NCT00136526
- Testing
- Docetaxel and Diethylstilbestrol (DES)
- Volunteers
- 30 people
- Sponsor
- University of Washington
Prostate Cancer, Stereotactic Body Radiation Therapy
START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor…
- Trial name
- START-MET (NCT05209243)
- Testing
- SBRT, STANDARD OF CARE
- Where
- 2 sites in Spain
- Volunteers
- 266 people
- Sponsor
- Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Prostate Cancer
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a…
- Trial name
- g-RAMPP (NCT02454543)
- Testing
- Radical prostatectomy, Best systemic therapy
- Where
- Germany
- Volunteers
- 452 people
- Sponsor
- Martini-Klinik am UKE GmbH
Hypogonadism, Hypogonadism, Male
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
The combination of testosterone and dutasteride is intended for use in hypogonadal men. This study will evaluate the bioavailability and pharmacokinetics of various doses of testosterone administered with and without dutasteride
- Trial name
- NCT00400335
- Testing
- Nanomilled testosterone, commercially available dutasteride, Nanomilled dutasteride
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ovarian Response
Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients
There is a decline in androgen concentration with ovarian aging. Also, ovarian response to COH in IVF cycles diminishes with ovarian aging.
- Trial name
- APPE (NCT00870025)
- Testing
- human chorionic gonadotropin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- IVI Madrid
Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
This phase I/II trial study evaluates the tolerability and best tolerated dose of the PI3K inhibitor GDC-0941 when given with the chemotherapy cisplatin.
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01918306
- Testing
- cisplatin, laboratory biomarker analysis, pharmacological study
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Obesity, Hyperandrogenemia
Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess
This study will test whether metformin administration can ameliorate androgen (male hormone) overproduction in overweight pubertal girls with androgen excess.
- Conditions
- Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
- Trial name
- NCT01422746
- Testing
- Metformin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Virginia
Prostate Cancer
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
For this study, unfavorable intermediate risk prostate cancer patients will select whether they are to be treated with the standard of care (SOC) 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic…
- Trial name
- NCT06397703
- Testing
- Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
- Where
- United States
- Volunteers
- 392 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Bone Health Observational Study
Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced…
- Trial name
- BHOS (NCT00632905)
- Where
- 40 sites in Canada
- Volunteers
- 599 people
- Sponsor
- CMX Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.